Log In
BCIQ
Print this Print this
 

H9N2 influenza A vaccine

  Manage Alerts
Collapse Summary General Information
Company Nanotherapeutics Inc.
DescriptionNon-adjuvanted whole-virus H9N2 vaccine using Vero cell culture manufacturing technology
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentPhase I/II
Standard IndicationInfluenza virus
Indication DetailsPrevent H9N2 avian influenza infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today